- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | KINTOR PHARMA-B (09939): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | 1 | HKEx | ||
| Do | KINTOR PHARMA-B (09939): CHANGE IN COMPOSITION OF THE NOMINATION COMMITTEE | - | HKEx | ||
| Do | KINTOR PHARMA-B (09939): TERMS OF REFERENCE OF THE NOMINATION COMMITTEE | - | HKEx | ||
| KINTOR PHARMACEUTICAL Aktie jetzt für 0€ handeln | |||||
| 10.06. | KINTOR PHARMA-B (09939): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON TUESDAY, 10 JUNE 2025 | 2 | HKEx | ||
| 28.05. | Kintor: Exclusive Global 20 Seats, China's Sole One! KT-939 Was Successfully Selected for 2025 NYSCC Inspiration Hive Zone | 330 | PR Newswire | SUZHOU, China, May 28, 2025 /PRNewswire/ -- In the newly announced entry list of the Inspiration Hive zone at the 2025 New York Society of Cosmetic Chemists (NYSCC) exhibition, Kintor's innovative... ► Artikel lesen | |
| 15.05. | Kintor Pharma shifts from cancer drugs to cosmetics as funds run low | 1 | Bamboo Works | ||
| 13.05. | KINTOR PHARMA-B (09939): (1) RE-ELECTION OF RETIRING DIRECTORS; (2) RE-APPOINTMENT OF AUDITOR; (3) GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES; ... | 1 | HKEx | ||
| 13.05. | KINTOR PHARMA-B (09939): NOTICE OF ANNUAL GENERAL MEETING | - | HKEx | ||
| 13.05. | KINTOR PHARMA-B (09939): FORM OF PROXY FOR USE AT ANNUAL GENERAL MEETING | - | HKEx | ||
| 08.05. | KINTOR PHARMA-B (09939): VOLUNTARY ANNOUNCEMENT - OFFICIAL COMMENCEMENT OF GLOBAL SALES BUSINESS OF WHITENING AND FRECKLE-REMOVING FUNCTIONAL COSMETIC ... | 1 | HKEx | ||
| 02.05. | KINTOR PHARMA-B (09939): VOLUNTARY ANNOUNCEMENT - SUPERIOR EFFICACY OF CLINICAL OBSERVATIONAL STUDY IN KX-826 IN COMBINATION WITH MINOXIDIL FOR THE TREATMENT ... | 1 | HKEx | ||
| 29.04. | KINTOR PHARMA-B (09939): ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT 2024 | - | HKEx | ||
| 29.04. | KINTOR PHARMA-B (09939): ANNUAL REPORT 2024 | - | HKEx | ||
| 17.04. | KINTOR PHARMA-B (09939): VOLUNTARY ANNOUNCEMENT - INCREASE IN SHAREHOLDING BY CHAIRMAN OF THE BOARD, EXECUTIVE DIRECTOR AND CHIEF EXECUTIVE OFFICER DR. ... | 1 | HKEx | ||
| 26.03. | KINTOR PHARMA-B (09939): ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2024 | - | HKEx | ||
| 20.03. | KINTOR PHARMA-B (09939): VOLUNTARY ANNOUNCEMENT - LONG-TERM SAFETY PHASE III CLINICAL TRIAL OF KX-826 FOR THE TREATMENT OF AGA REACHED PRIMARY ENDPOINT | 1 | HKEx | ||
| 12.03. | KINTOR PHARMA-B (09939): VOLUNTARY ANNOUNCEMENT - OPERATION COOPERATION AGREEMENT IN RELATION TO OVERSEAS MARKET OF COSMETICS | 2 | HKEx | ||
| 11.03. | KINTOR PHARMA-B (09939): DATE OF BOARD MEETING | 1 | HKEx |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 26,975 | +2,64 % | EQS-PVR: Bayer Aktiengesellschaft: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Stimmrechtsmitteilung: Bayer Aktiengesellschaft
Bayer Aktiengesellschaft: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung
23.06.2025... ► Artikel lesen | |
| MERCK KGAA | 112,65 | +0,90 % | MilliporeSigma and "Abbott Elementary" Inspire Students' Curiosity With Hands-On STEM | NORTHAMPTON, MA / ACCESS Newswire / June 25, 2025 / Between September 2024 and April 2025, MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, teamed up with... ► Artikel lesen | |
| EYENOVIA | 10,960 | +38,91 % | Eyenovia launches validator node for Hyperliquid blockchain | ||
| ASTRAZENECA | 120,05 | +0,42 % | Kaum Impulse für die AstraZeneca plc-Aktie (60,9091 €) | Der Kurs der der AstraZeneca plc-Aktie kommt kaum von der Stelle. Die Aktie kostete zuletzt 70,78 US-Dollar. Die Wertschätzung der Investoren für die Aktie von AstraZeneca plc hat sich heute kaum verändert.... ► Artikel lesen | |
| DERMAPHARM | 34,750 | 0,00 % | EQS-DD: Dermapharm Holding SE: Dr. Andreas Eberhorn, Kauf | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
24.06.2025 / 16:45... ► Artikel lesen | |
| ELI LILLY | 670,70 | -1,27 % | Eli Lilly and Company: Lilly declares third-quarter 2025 dividend | INDIANAPOLIS, June 23, 2025 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2025... ► Artikel lesen | |
| NOVO NORDISK | 59,27 | +1,06 % | Novo Nordisk: Kursrutsch nach Studiendaten-Schock! | Novo Nordisk steht nach enttäuschenden Studiendaten seines Adipositas-Mittels CagriSema unter Druck - Anleger hatten mehr erwartet. Die Aktie verliert deutlich an Wert, da das Konkurrenzprodukt Zepbound... ► Artikel lesen | |
| GSK | 16,510 | +0,24 % | GSK's Benlysta Autoinjector Gets FDA Approval For Children With Active Lupus Nephritis | LONDON (dpa-AFX) - GSK plc (GSK.L) Tuesday said that the U.S. Food and Drug Administration (FDA) has approved Benlysta autoinjector for individuals aged five years and older with active lupus... ► Artikel lesen | |
| ETON PHARMACEUTICALS | 14,030 | +0,50 % | Eton Pharmaceuticals to join Russell indexes | ||
| SCHOTT PHARMA | 28,300 | +0,71 % | Schott Pharma-Aktie leicht im Plus (28,50 €) | An der deutschen Börse liegt die Schott Pharma-Aktie zur Stunde im Plus. Der jüngste Kurs betrug 28,50 Euro. Die Schott Pharma-Aktie verzeichnet aktuell ein Kursplus von 1,42 Prozent. Sie hat sich um... ► Artikel lesen | |
| CITIUS PHARMACEUTICALS | 1,530 | +15,04 % | Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2025 Financial Results and Provides Business Update | CRANFORD, N.J., May 14, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated... ► Artikel lesen | |
| METSERA | 28,670 | -0,14 % | Metsera, Inc.: Metsera Announces Positive Phase 1 Data of First-in-Class Once-Monthly Amylin Candidate MET-233i | Placebo-subtracted mean weight loss up to 8.4% at Day 36 19-day observed half-life supports once-monthly dosing as monotherapy and potential first-in-category monthly GLP-1 + Amylin combination Well-tolerated... ► Artikel lesen | |
| HARROW | 30,880 | -1,50 % | Formosa Pharmaceuticals Inc.: Harrow Health, Inc. Acquires U.S. Commercial Rights to BYQLOVI (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals | TAIPEI, June 9, 2025 /PRNewswire/ -- Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, and Taiwan -based Formosa Pharmaceuticals... ► Artikel lesen | |
| ROCKET LAB | 30,710 | +1,59 % | Rocket Lab Corporation: Rocket Lab to Launch Electron Mission for European Space Agency's Next-Generation Navigation System | Rocket Lab Corporation (Nasdaq: RKLB) ("Rocket Lab" or the "Company"), a global leader in launch services and space systems, today announced it has been selected to launch a dedicated Electron mission... ► Artikel lesen | |
| VYNE THERAPEUTICS | 1,420 | -12,35 % | Pre-market Movers: Odyssey Marine Exploration, SES AI, VYNE Therapeutics, The OLB Group, Lexaria Bioscience | OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 08.30 A.M. ET).In the Green Odyssey Marine Exploration, Inc. (OMEX) is up over... ► Artikel lesen |
KINTOR PHARMACEUTICAL LTD gehört der Branche Pharma an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu KINTOR PHARMACEUTICAL LTD finden Sie auf Wallstreet Online.